Skip to main content

Advertisement

Table 3 Observed changes from baseline values over the study period (mean ± standard error)

From: Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy

   6 mo 12 mo 18 mo 24 mo
   Mean ± SEM P Mean ± SEM P Mean ± SEM P Mean ± SEM P
Cholesterol change E 11.5 ± 5.6 0.046 14.4 ± 5 0.005 15.3 ± 7 0.037 8.9 ± 7.4 NS
  O 16.8 ± 4.7 0.001 21.6 ± 4.1 <0.001 24 ± 5.3 <0.001 17 ± 6 0.009
HDL change E -4.3 ± 1.8 0.025 -3 ± 2.3 NS -6.5 ± 2.6 0.024 -8.3 ± 2.1 0.001
  O 2.2 ± 1.5 NS 1.7 ± 1.4 NS 1.5 ± 1.2 NS 1.1 ± 1.9 NS
LDL change E 24.3 ± 6.3 0.001 20.1 ± 6.3 0.004 22.7 ± 9.5 0.030 32.1 ± 8.1 0.001
  O 19.8 ± 5.7 0.002 22.3 ± 4.9 <0.001 30.4 ± 6.2 <0.001 23 ± 8.4 0.015
Total TRG change E -24.1 ± 7.8 0.004 -32.2 ± 7.6 <0.001 -26.8 ± 9.3 0.008 -20.7 ± 9.6 0.040
  O -13.7 ± 6.1 0.031 -17.6 ± 7.6 0.026 -9.4 ± 7.2 NS -19.8 ± 9 0.038
  1. E = exemestane; O = observation.
  2. Note: t-test P values, NS = nonsignificant when P > 0.05.